Do you wish to leave the site?
The TAVNEOS® Connect Team is here to:
For newly prescribed TAVNEOS® patients, this program can initially provide up to a 30-day supply:
To enroll your patients in the TAVNEOS® Connect Quick Start Program:
If your patient is eligible, after the pharmacy speaks to your patient to coordinate delivery, the Quick Start supply of TAVNEOS® will be shipped directly to your patient’s home. See complete submission details below.
Helpful tips for patients enrolling in the TAVNEOS® Connect Quick Start Program
For patients transitioning from an inpatient setting:
TAVNEOS® Connect services are available for adult patients whose diagnosis is aligned with the FDA-approved indication for TAVNEOS®. Additional eligibility criteria may apply.
Terms, conditions, and program maximums apply. Other restrictions may apply. This program is not open to patients receiving prescription reimbursement under any federal, state or government funded healthcare program, or for cash patients. This is not insurance or a guarantee of payment. No cash value. Void were prohibited by law.
Based on patient approval rates from October 2021 through December 2022.
Based on patient Start Forms from October 2021 through March 2023.
if patient needs quick start
Fax completed Start Form to the TAVNEOS® Connect Team
Option 2, then Option 1
|Hours:||8 AM to 8 PM ET, Monday-Friday|
|ePrescribe:||ARx Patient Solutions Pharmacy|
|Address:||4500 W 107th Street Overland Park,
IF PATIENT DOES NOT REQUIRE QUICK START
Fax completed Start Form and/or ePrescribe to ONE of the
Network Specialty Pharmacies
Option 2, then Option 2
Option 2, then Option 2
|Hours:||8 AM to 8 PM ET, Monday-Friday||8 AM to 8 PM ET, Monday-Friday|
|ePrescribe:||Amber Specialty Pharmacy||PANTHERx Rare Pharmacy|
|Address:||10004 South 152nd Street Omaha, NE 68138||24 Summit Park Drive Pittsburgh, PA 15275|
PLEASE NOTE: TAVNEOS® is a limited-distribution specialty product available commercially to patients only through select Specialty Pharmacy providers. Once all information is obtained and appropriate patient support is provided, the TAVNEOS® Connect Team will transfer the enrollment and Rx to the associated specialty pharmacy for continued support toward prescription fulfillment.
Do you wish to leave the site?
Serious hypersensitivity to avacopan or to any of the excipients.
Hepatotoxicity: Serious cases of hepatic injury have been observed in patients taking TAVNEOS, including life-threatening events. Obtain liver test panel before initiating TAVNEOS, every 4 weeks after start of therapy for 6 months and as clinically indicated thereafter. Monitor patients closely for hepatic adverse reactions, and consider pausing or discontinuing treatment as clinically indicated (refer to section 5.1 of the Prescribing Information). TAVNEOS is not recommended for patients with active, untreated, and/or uncontrolled chronic liver disease (e.g., chronic active hepatitis B, untreated hepatitis C, uncontrolled autoimmune hepatitis) and cirrhosis. Consider the risks and benefits before administering this drug to a patient with liver disease.
Serious Hypersensitivity Reactions: Cases of angioedema occurred in a clinical trial, including 1 serious event requiring hospitalization. Discontinue immediately if angioedema occurs and manage accordingly. TAVNEOS must not be readministered unless another cause has been established.
Hepatitis B Virus (HBV) Reactivation: Hepatitis B reactivation, including life-threatening hepatitis B, was observed in the clinical program. Screen patients for HBV. For patients with evidence of prior infection, consult with physicians with expertise in HBV and monitor during TAVNEOS therapy and for 6 months following. If patients develop HBV reactivation, immediately discontinue TAVNEOS and concomitant therapies associated with HBV reactivation, and consult with experts before resuming.
Serious Infections: Serious infections, including fatal infections, have been reported in patients receiving TAVNEOS. The most common serious infections reported in the TAVNEOS group were pneumonia and urinary tract infections. Avoid use of TAVNEOS in patients with active, serious infection, including localized infections. Consider the risks and benefits before initiating TAVNEOS in patients with chronic infection, at increased risk of infection, or who have been to places where certain infections are common.
The most common adverse reactions (≥5% of patients and higher in the TAVNEOS group vs. prednisone group) were nausea, headache, hypertension, diarrhea, vomiting, rash, fatigue, upper abdominal pain, dizziness, blood creatinine increased, and paresthesia.
Avoid coadministration of TAVNEOS with strong and moderate CYP3A4 enzyme inducers. Reduce TAVNEOS dose when coadministered with strong CYP3A4 enzyme inhibitors to 30 mg once daily. Monitor for adverse reactions and consider dose reduction of certain sensitive CYP3A4 substrates.
TAVNEOS is available as a 10 mg capsule.
TAVNEOS (avacopan) is indicated as an adjunctive treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (granulomatosis with polyangiitis [GPA] and microscopic polyangiitis [MPA]) in combination with standard therapy including glucocorticoids. TAVNEOS does not eliminate glucocorticoid use.